Tumor cell expressing Epstein-Barr virus antigen

The term "Tumor cell expressing Epstein-Barr virus antigen" refers to a malignant or transformed human cell that displays one or more proteins encoded by the Epstein-Barr virus (EBV) on its surface. These cells are typically found in certain cancers associated with chronic latent infection by EBV—including various lymphomas, nasopharyngeal carcinoma, and some gastric carcinomas. The presence of viral proteins such as LMP1, LMP2A/B, and nuclear antigens like EBNA1 is a hallmark of these malignancies. These viral gene products drive oncogenic processes through multiple mechanisms including promoting proliferation and inhibiting apoptosis; they also enable immune evasion via interference with host immune signaling pathways and suppression of apoptosis regulators like p53. Because these cells present unique foreign antigens not found in healthy tissue under normal conditions, they are considered promising targets for immunotherapy approaches—such as therapeutic vaccines or adoptive T-cell transfer—designed to selectively eliminate infected cancerous cells while sparing healthy tissue. However, challenges include genetic variability among viral genes across patients/tumors and potential for immune escape. Note: This entry is not a single molecular entity but rather describes a class of cancerous host cells defined by their expression of one or more foreign (viral) proteins; thus it does not map cleanly onto standard molecular target conventions such as "receptor" or "enzyme." For structured data purposes this should be flagged as an incorrect/non-canonical target name since it refers to a cellular phenotype rather than an individual molecule.

Other names

EBV-positive tumor cellEpstein-Barr virus antigen-expressing tumor cellEBV-associated malignant cell

Recognition and killing by cytotoxic T cells directed against viral antigens expressed on the tumor surface